After an incredibly successful inaugural year, the World Vaccine and Immunotherapy Congress is back in 2018 to bring you more content, learning and business development opportunities so you can take advantage of the rich biotech and funding environment that the West Coast offers.
Whilst still focussing on the vaccine and immunotherapy industry the scope of the event has expanded considerably and will delve deeper into topics surrounding vaccine development, cancer immunotherapy, funding and partnerships as well as exploring new topics in clinical trials & development, bioprocessing, manufacture and delivery, and the development and use of antibodies for both infectious diseases and cancer.
This is the congress for top decision makers of the vaccine and immunotherapy industry with both scientific and commercial interests, specifically interested in both learning and/or partnering.
No matter where your interest lies we have content, networking and potential partners for you.
Providing attendees one stop progressive scientific and strategic solutions to the vaccine and immunotherapy industry, through executive level commentary, case studies and real-time analysis from key stakeholders to bring about faster, more cost-effective and more efficacious vaccines.
Meet the key players from the Human Vaccines Project
- including all five universities and academics centers involved as well as senior members of the Scientific Steering Committee.
Hear exciting new research
from the directors some of the top cancer centers in the US as well as senior representatives from leading consortiums including the Parker Institute for Cancer Immunotherapy, AACR GENIE Project, the San Diego Center for Precision Immunotherapy and the Translational Genomics Research Institute (TGen).
Explore the latest methods and technologies
that allow better understanding of the immune system and improve vaccine development and other immunotherapy approaches against infectious diseases and cancer. This includes integrating synthetic biology, omics, immune profiling, bioinformatics, systems biology and new-generation adjuvants with break through immunotherapy immunomodulators like check point inhibitors and oncolytic viruses in combinational therapies.
Hear from C-Level executives from all the key vaccine developers
and thought leaders from pharma, biotech’s, academics and government, in a combined scientific and commercial environment where CRO’s, CMO’s, EQM’s, Biotech’s and platform technology organisations can demonstrate their latest products and services and do business.
Listen to updates on the latest discovery-stage infectious and non-infectious vaccines
and hear clinical phase I, II and III data from leading biotech’s, big pharma and regulatory experts.
Dr Biol. Sci. Alessandro Sette
Center Head, Division Head, and Professor Center for Infectious Disease
La Jolla Institute
Dr Steven Reed
Founder, President, and CSO
Infectious Disease Research Institute (IDRI)
Dr Peter Hotez MD PhD
Dean of the National School of Tropical Medicine
Baylor College of Medicine
Dr Karin Jooss
Executive Vice President of Research, and Chief Scientific Officer
Dr Jerald Sadoff
Janssen Infectious Diseases and Vaccines
Prof Bali Pulendran
Professor in the Department of Pathology and Laboratory Medicine
Emory University School of Medicine
Dr Roy Baynes
Senior Vice President, Global Clinical Development and Chief Medical Officer
Dr. Wayne C. Koff
President and CEO, The Human Vaccines Project
International Aids Vaccine Initiative Inc
Dr Maria Karasarides
Executive Director, ImmunoOncology
Dr Ezra Cohen
Professor of Medicine, UC San Diego Moores Cancer Center and Co-Director
San Diego Center for Precision Immunotherapy